CTOs on the Move

Denali Therapeutics

www.denalitherapeutics.com

 
Denali Therapeutics Inc. (“Denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Denali Therapeutics raised $217M on 05/14/2015

Similar Companies

Comfort Safety Products

Comfort Safety Products is a Lowell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pronutria

Amino acid biology is fundamental to life, regulating biological pathways critical to health. A variety of conditions occur when amino acid pathways become dysregulated.

Ultivue

Ultivue develops innovative reagent-based solutions that maximize the biological information available from cells and tissue samples. The company`s technology is being used to elucidate biological pathways and to validate clinically-relevant biomarkers. Ultivue is based in Cambridge, MA. Our culture provides an exceptional work environment fostering innovation and collaboration to make a difference collectively. Ultivue`s employees are bright, flexible, and driven to create meaningful impact through our work. We work at a fast pace, but support each other achieve the work/life balance that helps us thrive as a company. Our entrepreneurial culture relies on contributions and input from all. Our bench of experienced managers provides mentoring and support to ensure front line staff make the most of their unique talents and energy.

Axol Bioscience

We specialize in human cell culture. Whether you need iPSC-derived cells, disease models, human primary cells or culture media, were here for you.

Appia Bio

Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).